Cerevel Therapeutics 10-K 23 Nov 15 2015 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Aug. 31, 2015	Nov. 10, 2015	Feb. 28, 2015
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Aug. 31, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	FY
Entity Registrant Name	Ceres, Inc.
Entity Central Index Key	767,884
Current Fiscal Year End Date	--08-31
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		8,830,700
Entity Public Float			$ 11,527,325

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Aug. 31, 2015	Aug. 31, 2014
Current assets:
Cash and cash equivalents	$ 8,095	$ 3,423
Marketable securities		24,579
Prepaid expenses	$ 477	633
Accounts receivable	$ 577	370
Inventories		$ 84
Assets held for sale	$ 474
Other current assets	143	$ 240
Total current assets	9,766	29,329
Property and equipment, net	1,258	2,996
Other assets	98	99
Total long-term assets	1,356	3,095
Total assets	11,122	32,424
Current liabilities:
Accounts payable and accrued expenses	4,402	4,278
Billings in excess of costs	802	356
Deferred rent	$ 18	18
Current portion of long-term debt		70
Total current liabilities	$ 5,222	4,722
Deferred rent	56	$ 75
Common stock warrant liabilities	$ 1,631
Long-term debt, net of current portion		$ 18
Total liabilities	$ 6,909	$ 4,815
Commitments and contingencies
Stockholders' equity:
Common Stock, $0.01 par value; 240,000,000 shares authorized; 8,830,700 shares issued and outstanding at August 31, 2015; 6,024,108 shares issued and outstanding at August 31,2014	$ 88	$ 60
Additional paid-in capital	335,424	332,049
Accumulated other comprehensive loss	762	(595)
Accumulated deficit	(332,061)	(303,905)
Total stockholders' equity	4,213	27,609
Total liabilities and stockholders' equity	$ 11,122	$ 32,424

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Aug. 31, 2015	Aug. 31, 2014
Consolidated Balance Sheets [Abstract]
Common Stock, par value	$ 0.01	$ 0.01
Common Stock, shares authorized	240,000,000	240,000,000
Common Stock, shares issued	8,830,700	6,024,108
Common Stock, shares outstanding	8,830,700	6,024,108

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Aug. 31, 2015	Aug. 31, 2014
Revenues:
Product sales	$ 434	$ 146
Services	2,286	2,258
Total revenues	2,720	2,404
Cost and operating expenses:
Cost of product sales	5,267	3,021
Research and development	9,684	14,156
Selling, general and administrative	15,946	14,484
Total cost and operating expenses	30,897	31,661
Loss from operations	(28,177)	(29,257)
Interest expense	(30)	(68)
Interest income	28	$ 5
Other income	24
Loss before income taxes	(28,155)	$ (29,320)
Income tax expense	(1)	(1)
Net loss	$ (28,156)	$ (29,321)
Basic and diluted net loss per share attributable to common stockholders	$ (4.57)	$ (6.48)
Weighted average outstanding common shares used for net loss per shares attributable to common stockholders:
Basic and diluted	6,166,006	4,525,746

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Aug. 31, 2015	Aug. 31, 2014
Consolidated Statements of Comprehensive Loss [Abstract]
Net loss	$ (28,156)	$ (29,321)
Other comprehensive income (loss):
Foreign currency translation adjustments	1,346	100
Net unrealized gain (loss) on marketable securities	11	1
Total comprehensive loss	$ (26,799)	$ (29,220)

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Loss [Member]	Accumulated Deficit [Member]
Balance (in shares) at Aug. 31, 2013		3,112,147
Balance at Aug. 31, 2013	$ 33,006	$ 30	$ 308,256	$ (696)	$ (274,584)
Common stock issued upon offering, net of costs (shares)		2,875,000
Common stock issued upon offering, net of costs	20,751	$ 29	20,722
Restricted stock issued (in shares)		43,320
Restricted stock issued	$ 4	$ 1	$ 3
Restricted stock cancelled (in shares)		(6,359)
Restricted stock cancelled
Stock compensation expense	$ 3,068		$ 3,068
Net loss	(29,321)				$ (29,321)
Foreign currency translation adjustment	100			$ 100
Unrealized gain on marketable securities	1			1
Balance (in shares) at Aug. 31, 2014		6,024,108
Balance at Aug. 31, 2014	27,609	$ 60	$ 332,049	$ (595)	$ (303,905)
Common stock issued upon offering, net of costs (shares)		2,798,478
Common stock issued upon offering, net of costs	$ 1,138	$ 28	$ 1,110
Restricted stock issued (in shares)		9,125
Restricted stock issued
Restricted stock cancelled (in shares)		(1,011)
Restricted stock cancelled
Stock compensation expense	$ 2,265		$ 2,265
Net loss	(28,156)				$ (28,156)
Foreign currency translation adjustment	1,346			$ 1,346
Unrealized gain on marketable securities	11			11
Balance (in shares) at Aug. 31, 2015		8,830,700
Balance at Aug. 31, 2015	$ 4,213	$ 88	$ 335,424	$ 762	$ (332,061)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Aug. 31, 2015	Aug. 31, 2014
Cash flows from operating activities:
Net loss	$ (28,156)	$ (29,321)
Adjustments to reconcile net loss to net cash used in operating activities:
Change in fair value of common stock warrants	(24)
Impairment of assets	502
Net (loss) gain on disposal of assets	(39)	$ 385
Depreciation and amortization	657	1,517
Amortization of premiums on marketable securities	142	288
Stock compensation	2,265	3,068
Other	52	152
Changes in operating assets and liabilities:
Prepaid expenses	122	113
Accounts receivable	(208)	589
Inventories	65	(61)
Other assets	85	(21)
Accounts payables and accrued expenses	892	390
Billings in excess of costs	446	356
Deferred rent	(18)	(18)
Net cash used in operating activities	(23,217)	(22,563)
Cash flows from investing activities:
Purchases of property and equipment	(387)	(1,014)
Proceeds from sale of property and equipment	60	810
Purchase of marketable securities (at cost)	(720)	(33,085)
Maturities of marketable securities	25,116	29,700
Net cash provided by (used in) investing activities	24,069	(3,589)
Cash flows from financing activities:
Principal payments on debt	(69)	(159)
Proceeds from issuance of common stock and common stock warrants, net of underwriters discounts and commissions and offering expenses	2,794	20,751
Net cash provided by financing activities	2,725	20,592
Effect of foreign currency translation on cash	1,095	102
Net increase (decrease) in cash and cash equivalents	4,672	(5,458)
Cash and cash equivalents at beginning of period	3,423	8,881
Cash and cash equivalents at end of period	8,095	3,423
Supplemental cash flow information:
Interest paid during the year	30	46
Income taxes paid during the year	$ 1	$ 1

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Aug. 31, 2015
Summary of Significant Accounting Policies [Abstract]
Summary of Significant Accounting Policies	(1) Summary of Significant Accounting Policies Description of Business Ceres, Inc. (Company) is an agricultural biotechnology company that develops and markets seeds and traits to produce crops for feed, forages, sugar and other markets. The Company uses a combination of advanced plant breeding, biotechnology and bioinformatics to develop seed products and biotechnology traits to address many of the current limitations and future challenges facing agriculture. These technology platforms, which can increase crop productivity, improve quality, reduce crop inputs and improve cultivation on marginal land, have broad application across multiple end markets, including food, feed, fiber and fuel. In January 2010, the Company formed a subsidiary, Ceres Sementes do Brasil Ltda. The Company's ownership in this subsidiary is 99.9 99.9 On March 10, 2014, the Company completed a registered public offering of 23,000,000 3,000,000 1.00 20,800 On April 8, 2015, the Company filed an amendment to its amended and restated certificate of incorporation which effected a 1 for 8 reverse stock split of the Company's issued and outstanding shares of common stock. The par value of the common stock was not adjusted as a result of the reverse stock split. All issued and outstanding shares of common stock, warrants, and stock options and per share amounts contained in the Company's consolidated financial statements have been retroactively adjusted to reflect this reverse stock split for all periods presented. On July 30, 2015, the Company completed a registered public offering of an aggregate of 1,200,000 0.01 1.296 1.0 one 1.62 24,000 1.944 On August 26, 2015, the Company completed a registered public offering of an aggregate of 1,598,478 0.01 1.22 1.7 0.75 1,198,859 1.22 The Company also issued warrants to purchase an aggregate of 31,970 1.83 Liquidity The Company has incurred substantial net losses from operations since its inception, including net losses of $ 28,156 29,321 332,061 As of August 31, 2015, the Company had cash and cash equivalents of $ 8,095 The Company has incurred recurring losses and expects to incur additional losses related to the continued development of its business, including research and development, seed production and operations, and sales and marketing. There is no assurance that the Company will achieve profitable operations, or if achieved, can be sustained on a continued basis. Restructuring On October 11, 2013, the Company commenced the implementation of a plan (Plan) intended to further align expenditures with the Company's near-term commercial opportunity in Brazil, shift Northern Hemisphere sorghum breeding activities from College Station, Texas to a more appropriate location, de-emphasize research and development for U.S. cellulosic feedstocks, reduce costs and conserve cash. The actions taken under the Plan, which included, among others, a workforce reduction that impacted 16 August 31, 2014 . During 2014, the Company incurred total charges of approximately $ 1,600 900 400 300 1,600 1,000 500 100 On June 19, 2015, the Company announced the continued realignment of its business to focus on food and forage opportunities and biotechnology traits for sugarcane and other crops. As part of the realignment, the Company undertook a restructuring of its Brazilian seed operations. The restructuring of the Company's Brazilian seed operations, includes, among other actions, a workforce reduction that initially impacted 14 2 600 100 500 $500 100 19 800 100 700 200 600 Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with the accounting principles generally accepted in the United States of America (GAAP) and with the Rules and Regulations of the Securities and Exchange Commission. The consolidated financial statements include the accounts of the Company and its subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions. This affects the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant items subject to such estimates and assumptions include the valuation of assets held for sale, inventory, deferred tax assets, common stock, stock options, and liability classified warrants. Actual results could differ from those estimates. Cash Equivalents The Company considers all highly liquid investments, with an original maturity of three months or less when purchased, to be cash equivalents. Cash equivalents totaled $ 3,792 2,174 Marketable Securities Marketable securities are classified as available for sale and are recorded at fair value, with the unrealized gains and losses, if any, net of taxes, reported as a component of shareholders' equity until realized or until a determination is made that an other-than-temporary decline in market value has occurred. In determining whether an other-than-temporary impairment exists for debt securities, management considers: (1) the length of time and the extent to which the fair value has been less than cost, (2) the financial condition and near-term prospects of the issuer and (3) the intent and ability of the Company to retain its investment in the issuer for a period of time sufficient to allow for any anticipated recovery in fair value. Management has determined that there has been no other-than-temporary impairment of its marketable securities. The cost of marketable securities sold is based upon the specific identification method and any realized gains or losses on the sale of investments are reflected as a component of interest income or expense. There were no sales of marketable securities during the years ended August 31, 2015 and 2014. The Company classifies marketable securities as current or non-current based upon whether such assets are reasonably expected to be realized in cash or sold or consumed during the normal operating cycle of the business. Financial Instruments The carrying value of financial instruments such as cash and cash equivalents, accounts receivables, accounts payable, and accrued expenses approximate their fair value due to the short-term nature of these instruments. At each period end, the fair value of the long-term debt approximated carrying value based on interest rates currently available to the Company. Fair Value of Financial Instruments Assets and liabilities recorded at fair value in the consolidated financial statements are categorized based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels that are directly related to the amount of subjectivity associated with the inputs to the valuation of these assets or liabilities are as follows: • Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company can access at the measurement date. • Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. • Level 3 inputs are unobservable inputs for the asset or liability. The following tables present the Company's financial assets that were measured at fair value on a recurring basis as of August 31, 2015 and 2014 by level within the fair value hierarchy: August 31, 2015 Level 1 Level 2 Level 3 Total Financial Assets Money market funds $ 3,732 $ — $ — $ 3,732 Certificates of deposit — available for sale — 60 — 60 Total $ 3,732 $ 60 $ — $ 3,792 All of the money market funds and certificates of deposit are included in cash and cash equivalents on the consolidated balance sheets. August 31, 2014 Level 1 Level 2 Level 3 Total Financial Assets Money market funds $ 2,114 $ — $ — $ 2,114 Certificates of deposit — available for sale — 4,240 — 4,240 Commercial paper — available for sale — 5,249 — 5,249 Corporate bonds — available for sale — 15,150 — 15,150 Total $ 2,114 $ 24,639 $ — $ 26,753 All of the money market funds and $ 60 Financial Liabilities Certain common stock warrants have been classified as liabilities due to some features which could enable the holder to receive cash. 1,631 The fair value of the common stock warrant liabilities at August 31, 2015 was estimated using the following weighted-average assumptions: Year Ended August 31, 2015 Expected term (in years) 4.91 5.49 Expected volatility 69.80 Risk free interest rate 1.54 Expected dividend yield 0 Accounts Receivable Accounts receivable represents amounts owed to the Company from product sales and collaborative research and government grants. The Company had no amounts reserved for doubtful accounts at August 31, 2015 and 2014 as the Company expected full collection of the accounts receivable balances. Customers representing greater than 10% of accounts receivable were as follows (in percentages): As of Customers 2015 2014 Customer B 23.7 59.5 Customer E 18.9 25.9 Customer F 38.2 ** Customer G 16.1 ** ** No balance Customers representing greater than 10% of revenues were as follows (in percentages): Year Ended August 31, Customers 2015 2014 Customer A ** 17.5 Customer B 33.5 41.9 Customer E 12.2 16.5 Customer F 13.1 11.6 Customer I 11.9 ** ** No revenue Inventories and Inventory Valuation At August 31, 2015, inventory was fully reserved. At August 31, 2014, seed inventory consisted of work-in-process and finished goods for costs related to the Company's sorghum seeds in Brazil. When inventory costs exceed expected market value due to obsolescence or lack of demand, inventory write-downs are recorded for the difference between the cost and the market value in the period based on the Company's evaluation of such inventory. Property and Equipment Property and equipment is stated at cost. Depreciation is provided using the straight-line method over the shorter of the estimated useful lives or the remaining life of the lease. Depreciation periods for the Company's property and equipment are as follows: Automobiles and trucks 3 5 Office, laboratory, farm and warehouse equipment and furniture 3 5 Leasehold improvements 3 10 Buildings 14 39 Assets Held for Sale The Company reclassifies long-lived assets to Assets Held for Sale when all required criteria for such reclassification are met. The assets are recorded at the lower of the carrying value or fair value less costs to sell. Assets held for sale must meet the following conditions: (1) management, having authority to approve the action, commits to a plan to sell the asset, (2) the asset is available for immediate sale in its present condition, (3) an active program to locate a buyer and other actions required to complete the plan to sell the asset have been initiated, (4) the sale of the asset is probable, and transfer of the asset is expected to qualify for recognition as a completed sale, within one year, (5) the asset is being actively marketed for sale at a price that is reasonable in relation to its current fair value, and (6) actions required to complete the plan indicate that it is unlikely that significant changes to the plan will be made or that the plan will be withdrawn. In connection with an agreement the Company entered into on March 31, 2014 to sell its facility and certain equipment located in College Station, Texas, a determination was made that the assets met the criteria to be classified as held for sale and the fair value for the related assets was in excess of their carrying amount. Accordingly, the Company recorded a charge of $ 464 1,152 688 688 395 869 474 Fair value of the assets held for sale was determined using an appraisal for certain assets and resale information available for certain assets. Impairment of Long-Lived Assets Long-lived assets, such as property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. To the extent that an impairment indicator has occurred, recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset exceeds the fair value of the asset. Stock-Based Compensation The Company accounts for stock-based compensation arrangements with employees using a fair value method under ASC Topic 718, Compensation – Stock Compensation, The fair value method requires the Company to estimate the fair value of stock-based payment awards on the date of grant using an option pricing model. The Company uses an option pricing model to estimate the fair value of stock options granted that are expensed on a straight-line basis over the vesting period. The Company accounts for stock options issued to non-employees based on the estimated fair value of the awards using the option pricing model. The measurement of stock-based compensation to non-employees is subject to periodic adjustments as the underlying equity instruments vest, and the resulting change in value, if any, is recognized in the Company's consolidated statements of operations during the period the related services are rendered. The Company accounts for restricted stock awards based on the quoted market price of the Company's common stock on the date of grant that are expensed on a straight-line basis over the vesting period. Revenue Recognition Revenues are recognized when the following criteria are met: (1) persuasive evidence of an arrangement exists; (2) transfer of product or technology has been completed or services have been rendered; (3) the fee is fixed or determinable; and (4) collectability is reasonably assured. To date, the Company's primary source of revenues has been derived from collaborative research agreements and government grants and to a lesser extent, product sales. Product Sales Product sales are derived from seed and biomass sales, and trait fees. Product sales are recognized, net of discounts and allowances, once passage of title and risk of loss have occurred and contractually specified acceptance criteria have been met, provided all other revenue recognition criteria have also been met. Collaborative Research and Government Grants From time to time, the Company has entered into research and development collaboration agreements with third parties, including a large agriculture supplier, a consumer goods conglomerate and several biofuel producers. In addition, the Company has received grants from government agencies such as the Department of Energy (DOE) and the United States Department of Agriculture (USDA). The research and development collaboration agreements typically provide the Company with multiple revenue streams, which may include up-front, non-refundable fees for licensing certain of the Company's technologies, government grants and fees for research and development activities, and contingent milestone payments based upon achievement of contractual criteria. • Technology License Fees • Government Grants — The Company receives payments from government entities in the form of government grants. Government grants generally provide the Company with cost reimbursement for certain types of expenditures in return for research and development activities over a contractually defined period, as well an allocated portion of overhead expenses. Revenues from government grants are recognized in the period during which the related costs are incurred, provided substantially all the conditions under which the government grants were provided have been met and the Company has only perfunctory obligations outstanding. • Research and Development Fees • Milestone Fees The Company has earned research funding revenues from several agreements with the DOE, the USDA, USAID and several leading biofuel producers whereby the Company performed research activities and received revenues that partially reimbursed its expenses incurred. Under such grants and agreements, the Company retained a proprietary interest in the products and technology it developed. These expense reimbursements primarily consisted of direct expense sharing arrangements. The Company recorded revenue related to these grants and collaboration agreements of approximately $ 1,630 1,980 Software and Services During the years ended August 31, 2015 and 2014, the Company provided services related to software arrangements that involve (1) significant production, modification or customization and (2) post contract customer support (PCS). The customer has the option, annually, to extend the arrangement or elect to receive only maintenance. The Company does not have vendor specific objective evidence (VSOE) related to these components. In addition, there are substantive acceptance provisions related to the production, modification or customization. The company applies the completed contract method to the arrangement. However, only costs related to the production, modification or customization are deferred. Revenue is recognized upon acceptance of the production, modification or customization as that is later that the expiration of the annual PCS period. Revenue related to these arrangements was $ 656 278 The Company also had an arrangement that included a license, installation services and PCS. As the Company does not have VSOE for the elements, the Company has billings in excess of cash until PCS is the only undelivered element and will recognize revenue over the remaining PCS period. There was no revenue related to these arrangements during 2015 and 2014. Billings in Excess of Costs Research and Development Research and development expenses principally consist of personnel costs related to the Company's research and development staff as well as depreciation of research and development assets. Research and development expenses also include costs incurred for laboratory supplies, reimbursable costs associated with government grants and collaborative agreements, third-party contract payments, consultants, facility and related overhead costs. Income Taxes The Company accounts for income taxes in accordance with ASC 740, Income Taxes The Company accounts for unrecognized tax benefits also in accordance with ASC 740, Income Taxes August 31, 2015 and 2014, and did not recognize interest or penalties in the Statements of Operations during the years ended August 31, 2015 and 2014. The major jurisdictions in which the Company files income tax returns include the federal and state jurisdictions within the United States and Brazil, where it has a subsidiary. The tax years after 2009 remain open to examination by federal and state taxing jurisdictions and the tax years after 2011 remain open to examination by foreign jurisdictions. However, the Company has NOLs beginning in 1998 which would cause the statute of limitations to remain open for the year in which the NOL was incurred. Foreign Currency Translation The Brazilian real is the functional currency of the Company's subsidiary in Brazil and the Mexican Peso is the functional currency of the Company's subsidiary in Mexico. Accordingly, assets and liabilities of those operations are translated into United States dollars using the current exchange rate in effect at the balance sheet date and equity accounts are translated into United States dollars using historical rates. Revenues and expenses are translated at the weighted average rate of exchange during the reporting period. Gains and losses from foreign currency translation adjustments are represented as a component of accumulated other comprehensive loss. Accumulated Other Comprehensive Loss The Company's unrealized gains and losses on available-for-sale securities and foreign currency translation adjustments represents the components of comprehensive loss and have been disclosed in the consolidated statements of stockholders' equity. The following summarizes the changes in the balances of each component of accumulated comprehensive income (loss) during the years presented: Accumulated Foreign Unrealized Other Currency Gains (Losses) Comprehensive Translation on Securities Loss Balance at August 31, 2013 $ (684 ) $ (12 ) $ (696 ) Comprehensive gain 100 1 101 Balance at August 31, 2014 (584 ) (11 ) (595 ) Comprehensive gain 1,346 11 1,357 Balance at August 31, 2015 $ 762 $ - $ 762 Basic and Diluted Net Loss Per Share Basic net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding. Diluted net loss per common share is computed by dividing net loss available to common stockholders by the weighted average number of common shares and dilutive potential common share equivalents then outstanding, to the extent they are dilutive. Potential common shares consist of shares issuable upon the exercise of stock options and warrants (using the treasury stock method), and the weighted average conversion of the convertible preferred stock into shares of common stock (using the if-converted method). Dilutive net loss per share is the same as basic net loss per share for all periods presented because the effects of potentially dilutive items were anti-dilutive. The following potentially dilutive, common share equivalents were excluded from the calculation of diluted net loss per common share because their effect was anti-dilutive for each of the periods presented: Year Ended August 31, 2015 2014 Options to purchase common stock 409,763 396,504 Warrants to purchase common stock 2,775,083 320,255 Total 3,184,846 716,759 Segment information Management has determined that it has one business activity and operates in one segment as it only reports financial information on an aggregate and consolidated basis to its Chief Executive Officer, who is the Company's chief operating decision maker. Recent Accounting Pronouncements In July 2013, the FASB issued ASU 2013-11, Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists. In May 2014, the Financial Accounting Standards Board issued the Accounting Standards Update (“ASU”) 2014-09 Revenue from Contracts with Customers (Topic 606) For a public entity, ASU 2014-09 is effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. Early application is not permitted. An entity must apply ASU 2014-09 using either the full retrospective approach, by restating all years presented, or the cumulative effect at the date of adoption approach. We are currently assessing the impact that these changes will have on our consolidated financial statements and therefore are unable to quantify such impact or determine the method of adoption. In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements - Going Concern Sub-topic 205-40. The new guidance addresses management's responsibility to evaluate whether there is substantial doubt about an entity's ability to continue as a going concern and to provide related footnote disclosures. This ASU is effective for interim and annual periods beginning on or after December 15, 2016, and early adoption is permitted. The Company does not expect the adoption of this guidance to have a material impact on its financial position or results of operations.

Marketable Securities

Marketable Securities	12 Months Ended
	Aug. 31, 2015
Marketable Securities [Abstract]
Marketable Securities	(2) Marketable Securities At August 31, 2015, there were no marketable securities At August 31, 2014, marketable securities classified as available for sale consisted of the following: August 31, 2014 Gross Gross Amortized Unrealized Unrealized Available for sale securities Cost Gain Loss Fair Value Certificates of Deposit $ 4,244 $ - $ (4 ) $ 4,240 Commercial Paper 5,249 - - 5,249 Corporate Bonds 15,157 - (7 ) 15,150 Total $ 24,650 $ - $ (11 ) $ 24,639 At August 31, 2014, $ 60 1,199 There were no marketable securities classified as held-to maturity as of August 31, 2015 and 2014, respectively. All marketable securities at August 31, 2014 are due to mature in one year or less.

Inventories

Inventories	12 Months Ended
	Aug. 31, 2015
Inventories [Abstract]
Inventories	(3) Inventories At August 31, 2015, inventory was fully reserved. August 31, 2014 Work in process $ 20 Seed inventory 64 Total inventories $ 84

Property and Equipment

Property and Equipment	12 Months Ended
	Aug. 31, 2015
Property and Equipment [Abstract]
Property and Equipment	(4) Property and Equipment Property and equipment are summarized as follows: As of August 31, 2015 2014 Land $ 43 $ 43 Automobiles and trucks 44 1,113 Buildings 1,215 1,215 Office, laboratory, farm and warehouse equipment and furniture 10,863 12,718 Leasehold improvements 5,659 5,659 17,824 20,748 Less accumulated depreciation and amortization (16,566 ) (17,752 ) Property and equipment, net $ 1,258 $ 2,996

Accounts Payable and Accrued Ex

Accounts Payable and Accrued Expenses	12 Months Ended
	Aug. 31, 2015
Accounts Payable and Accrued Expenses [Abstract]
Accounts Payable and Accrued Expenses	(5) Accounts Payable and Accrued Expenses Accounts payable and accrued expenses consisted of the following: As of August 31, 2015 2014 Accounts payable $ 2,000 $ 1,406 Accrued payroll and related expenses 1,581 2,303 Research and development contracts 283 123 Taxes 395 - Other 143 446 $ 4,402 $ 4,278

Long-Term Debt

Long-Term Debt	12 Months Ended
	Aug. 31, 2015
Long-Term Debt [Abstract]
Long-Term Debt	(6) Long-Term Debt There were no long-term debt obligations as of August 31, 2015. Long-term debt as of August 31, 2014 is summarized as follows: As of August 31, 2014 Capital Leases $ 88 Less current portion (70 ) $ 18

Stock-Based Compensation

Stock-Based Compensation	12 Months Ended
	Aug. 31, 2015
Stock-Based Compensation [Abstract]
Stock-Based Compensation	(7) Stock-Based Compensation Equity Plans The Company has established three equity plans: the Ceres, Inc. 2000 Stock Option/Stock Issuance Plan (2000 Plan), the Ceres, Inc. 2010 Stock Option/Stock Issuance Plan (2010 Plan) and the Amended and Restated Ceres, Inc. 2011 Equity Incentive Plan (2011 Plan, and collectively with the 2000 Plan and the 2010 Plan, the Equity Plans). The Equity Plans provide for grants of Incentive Stock Options (ISOs) to employees and Nonqualified Stock Options (NSOs), stock and restricted stock to employees, directors, and consultants. In addition, the 2011 Plan provides for the grant of other equity based awards such as restricted stock units, stock appreciation rights and deferred stock to employees, directors and consultants. The option term, as determined by the Company's Board of Directors, may not exceed ten years. Vesting, also determined by the Company's Board of Directors, generally occurs ratably over four to five years. ISOs and NSOs may be granted at a price per share of not less than the fair market value at the date of grant. The total number of shares reserved for issuance under the Equity Plans is 844,374 187,500,000 135,456 Stock Option Valuation and Compensation The Company uses a Black Scholes option pricing model to determine the fair value of stock options. The weighted average grant date fair value of stock option awards was $ 3.04 7.28 The weighted average grant date estimated fair value of the Company's common stock was $ 3.76 10.24 The fair value of employee stock options was estimated using the following weighted-average assumptions: Year ended August 31, 2015 2014 Expected term (in years) 5.50-6.08 5.50-6.08 Expected volatility 79 -83 % 83 -87 % Risk free interest rate 1.66 -2.06 % 1.62 -2.04 % Expected dividend yield 0 % 0 % Expected Term — Expected Volatility — Risk-Free Interest Rate — Expected Dividend Yield — Stock-based compensation expense included in operating expenses is as follows: Year ended August 31, 2015 2014 Stock-based compensation costs for employee stock options $ 2,270 $ 3,074 Fair value changes of collaboration warrants (5 ) (6 ) Total stock-based compensation costs included in operating expenses $ 2,265 $ 3,068 Stock Option Activity The following summarizes the stock option transactions under the Equity Plans during the periods presented: Weighted Average Shares Exercise Price Options outstanding at August 31, 2013 348,830 $ 59.92 Options granted 98,004 10.16 Options forfeited (50,330 ) 67.60 Options outstanding at August 31, 2014 396,504 46.62 Options granted 41,738 3.75 Options forfeited (28,479 ) 23.41 Options outstanding at August 31, 2015 409,763 $ 43.87 The following table summarizes information about stock options outstanding and exercisable at August 31, 2015: Weighted- Weighted- Remaining Average Number Remaining Average Range of Number Contractual Exercise Vested and Contractual Exercise Exercise Price Outstanding Life Price Exercisable Life Price $ 1.96 5.06 36,004 9.52 $ 4.00 187 8.76 $ 5.06 $ 7.26 15.60 137,803 5.26 $ 12.24 134,754 5.19 $ 12.30 $ 26.24 32.40 56,831 3.50 $ 29.53 50,326 2.95 $ 29.83 $ 45.68 61.60 103,286 3.67 $ 54.93 102,719 3.65 $ 54.91 $ 96.80 137.28 75,839 6.26 $ 113.77 58,178 6.24 $ 114.68 409,763 346,164 No tax benefits were recorded on compensation costs recognized during the years ended August 31, 2015 and 2014. As of August 31, 2015 and 2014, there were $ 1,159 2,993 Restricted Stock Activity The following summarizes the restricted stock transactions under the Equity Plans for the periods presented: Weighted Average Grant Date Shares Fair Value Restricted stock outstanding and unvested at August 31, 2013 36,311 $ 44.40 Restricted stock granted 41,032 $ 10.48 Restricted stock vested (32,877 ) $ 16.96 Restricted stock forfeited (6,648 ) $ 38.00 Restricted stock outstanding and unvested at August 31, 2014 37,818 $ 32.58 Restricted stock granted 9,125 $ 4.20 Restricted stock vested (8,690 ) $ 36.63 Restricted stock forfeited (1,011 ) $ 12.77 Restricted stock outstanding and unvested at August 31, 2015 37,242 $ 25.17 As of August 31, 2015, there was $ 91 Stock Activity During the fiscal year 2014, the Company granted 2,288 7.28 16.7

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Aug. 31, 2015
Stockholders' Equity [Abstract]
Stockholders' Equity	(8) Stockholders' Equity Common Stock On March 7, 2014, the Company held its 2014 Annual Meeting of Stockholders (Annual Meeting). At the Annual Meeting, the stockholders approved an amendment to the Company's Amended and Restated Certificate of Incorporation which decreased the total number of shares of common stock of the Company from 490,000,000 Preferred Stock Pursuant to the Company's amended and restated certificate of incorporation, the Company is authorized to issue 10,000,000 Common Stock Warrants Financing Warrants issued in connection with Noble Agreement In May 2006, the Company entered into a collaboration agreement with The Samuel Roberts Noble Foundation, Inc. (Noble) (Noble Agreement) to establish a research program (see Note (12)). In connection with this collaboration, the Company granted Noble a warrant to purchase 16,667 240.00 4,167 624.4 16,667 In June 2011, the Company and Noble agreed to modify the warrants issued to Noble as follows: the warrant vests in equal installments of 4,167 Warrants issued in connection with TAMU Agreement In August 2007, the Company entered into a sponsored research and intellectual property rights agreement with The Texas A&M University System (TAMU) to establish a research program (see Note (12)). In connection with this collaboration, the Company granted TAMU a warrant to purchase 8,333 240.00 0 0 0.74 72.1 0 In December 2011, pursuant to an Amended and Restated Intellectual Property Rights Agreement (IP Rights Agreement) (see Note (12)), the Company issued warrants to TAMU to purchase 8,333 114.40 1.8 3.8 2.21 88.9 0 Warrants issued in connection with March 10, 2014 registered public offering On March 10, 2014 the Company issued warrants to purchase an aggregate of 60,000 12 305 1.64 84.2 0 Warrants issued in connection with the July 30, 2015 registered public offering On July 30, 2015 the Company issued warrants exercisable for one share of Common Stock for each share purchased in the July 30, 2015 offering for an aggregate of 1,200,000 1.62 760.0 1.62 69.50 5.5 0 755.6 1.54 69.80 5.41 0 The Company also issued warrants to purchase an aggregate of 24,000 1.944 13.3 1.62 69.50 5.0 0 13.2 1.62 69.80 4.9 0 Warrants issued in connection with the August 26, 2015 registered public offering On August 26, 2015, the Company issued warrants exercisable for 0.75 1,198,859 1.22 863.5 1.49 69.80 5.5 0 844.2 1.54 69.80 5.5 0 The Company also issued warrants to purchase an aggregate of 31,970 1.83 18.7 1.49 69.80 5.0 0 18.3 1.54 69.80 5.0 0

Income Taxes

Income Taxes	12 Months Ended
	Aug. 31, 2015
Income Taxes [Abstract]
Income Taxes	(9) Income Taxes Deferred tax benefits associated with deferred tax assets are offset by a corresponding valuation allowance. Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and amounts used for income tax purposes. Income tax expense attributable to loss before income taxes consisted of the following: Current Deferred Total Year ended August 31, 2015 U.S. federal $ — $ — $ — State and local 1 — 1 $ 1 $ — $ 1 Current Deferred Total Year ended August 31, 2014 U.S. federal $ — $ — $ — State and local 1 — 1 $ 1 $ — $ 1 Income tax expense differs from the amount computed by applying the federal corporate income tax rate of 34 : Year Ended Year Ended August 31, August 31, 2015 2014 Computed “expected” tax expense $ (9,584 ) $ (9,969 ) Increase (reduction) in income taxes resulting from: Stock-based compensation 625 774 State and local income taxes, net of federal income tax benefit 1 1 Foreign rate differential — — Warrants modification and changes in fair value — — Other 21 12 Change in valuation allowance 8,937 9,183 Income tax expense $ 1 $ 1 The following table summarizes the tax effects of temporary differences that give rise to significant portions of the deferred tax assets and liabilities at each period end: August 31, August 31, 2015 2014 Deferred tax assets: Accrued liabilities $ 240 $ 279 Other assets 157 169 Inventory capitalization 266 446 Deferred revenue 348 139 Total current deferred tax assets 1,011 1,031 Noncurrent assets: Depreciation 1,834 2,310 Inventory reserves 2,973 2,689 Deferred rent 22 29 Other assets 1,013 859 Net operating loss carryforward 112,373 101,485 Federal and state tax credit carryforward 8,919 8,919 Total noncurrent deferred tax assets 127,133 116,291 Total deferred tax assets 128,145 117,323 Less valuation allowance (128,145 ) (117,323 ) Net deferred tax assets $ — $ — As of August 31, 2015, the Company had $ 273,908 196,789 25,833 2018 2035 2015 2035 911 957 17 8,907 2029 In accordance with Internal Revenue Code (IRC) Sections 382 and 383, the annual utilization of net operating loss carryforwards and credits is limited if a change in control occurs, including a change resulting from an initial public offering. The Company has not completed a Section 382 analysis to determine if a change in ownership has occurred. Until such analysis is completed, there are no assurances that the existing net operating loss carryforwards or credits are not subject to significant limitation. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income, and tax planning strategies in making this assessment. Based upon the historical taxable income (loss) and projections for future taxable income (loss) over the periods in which the deferred tax assets are deductible, management believes it is more likely that the Company will not realize the benefits of these deductible differences. Accordingly, the Company has established a full valuation allowance of $128,145 and $117,323 for the years ended August 31, 2015 and 2014, respectively.

401(k) Benefit Plan

401(k) Benefit Plan	12 Months Ended
	Aug. 31, 2015
401(k) Benefit Plan [Abstract]
401(k) Benefit Plan	(10) 401(k) Benefit Plan The Company has a 401(k) profit sharing plan (the Plan) which covers substantially all employees of the Company. Plan participants may make voluntary contributions of up to 60 50 4 25 25 132 207

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Aug. 31, 2015
Commitments and Contingencies [Abstract]
Commitments and Contingencies	(11) Commitments and Contingencies The Company leases certain of its facilities and equipment under various noncancelable operating leases expiring through 2020 In connection with one of its facilities leases, the Company received a reimbursement for leasehold improvements of $ 270 457 440 Future minimum payments under noncancelable operating leases as of August 31, 2015 are as follows: Operating leases 2016 $ 621 2017 606 2018 618 2019 631 2020 51 Total minimum lease payments $ 2,527

Research Collaboration Agreemen

Research Collaboration Agreements	12 Months Ended
	Aug. 31, 2015
Research Collaboration Agreements [Abstract]
Research Collaboration Agreements	(12) Research Collaboration Agreements The Company has a number of research agreements with academic collaborators, including among others, TAMU, Noble, and the Institute of Crop Sciences of the Chinese Academy of Agricultural Sciences. In connection with these agreements, the Company receives certain exclusive options or licensing rights to technology and intellectual property developed under these agreements. The Company expenses amounts under these agreements to research and development expense in the period in which the services are rendered. The Company also licenses technology from third parties. Initial payments under these license agreements are capitalized and expensed on a straight-line basis over the license term. Noble Agreement In May 2006, the Company entered into a collaboration agreement with Noble to establish a research program. Under the Noble Agreement, the Company agreed to fund certain research activities undertaken by Noble in an amount up to $ 3,800 Under the collaboration agreement, in August 2012 the Company agreed to fund certain research activities undertaken by Noble through July 31, 2013 and 2014 of $ 82.7 85.3 TAMU Agreement In August 2007, the Company entered into a Sponsored Research and Intellectual Property Rights agreement with TAMU to establish a research program. Under the agreement, the Company agreed to fund certain research activities undertaken by TAMU in an amount up to $ 5,100 On September 24, 2011, the Company entered into an Amended and Restated Sponsored Research Agreement and an Amended and Restated Intellectual Property Rights Agreement (the “IP Rights Agreement”) with TAMU which both expire on September 23, 2026. The specific research projects and budgets undertaken pursuant to such agreement will be determined by an Executive Committee comprised of two members from each of TAMU and the Company as set forth in the Amended and Restated Sponsored Research Agreement. In December 2011, pursuant to the IP Rights Agreement, the Company issued warrants to TAMU to purchase 8,333 shares of common stock at an exercise price of $114.40 per share (see Note (9)). At August 31, 2015, the future minimum payments under the Company's research collaboration agreements are as follows: 2016 $ 602 2017 50 $ 652

Summary of Significant Accoun20

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Aug. 31, 2015
Summary of Significant Accounting Policies [Abstract]
Description of Business	Description of Business Ceres, Inc. (Company) is an agricultural biotechnology company that develops and markets seeds and traits to produce crops for feed, forages, sugar and other markets. The Company uses a combination of advanced plant breeding, biotechnology and bioinformatics to develop seed products and biotechnology traits to address many of the current limitations and future challenges facing agriculture. These technology platforms, which can increase crop productivity, improve quality, reduce crop inputs and improve cultivation on marginal land, have broad application across multiple end markets, including food, feed, fiber and fuel. In January 2010, the Company formed a subsidiary, Ceres Sementes do Brasil Ltda. The Company's ownership in this subsidiary is 99.9 99.9 On March 10, 2014, the Company completed a registered public offering of 23,000,000 3,000,000 1.00 20,800 On April 8, 2015, the Company filed an amendment to its amended and restated certificate of incorporation which effected a 1 for 8 reverse stock split of the Company's issued and outstanding shares of common stock. The par value of the common stock was not adjusted as a result of the reverse stock split. All issued and outstanding shares of common stock, warrants, and stock options and per share amounts contained in the Company's consolidated financial statements have been retroactively adjusted to reflect this reverse stock split for all periods presented. On July 30, 2015, the Company completed a registered public offering of an aggregate of 1,200,000 0.01 1.296 1.0 one 1.62 24,000 1.944 On August 26, 2015, the Company completed a registered public offering of an aggregate of 1,598,478 0.01 1.22 1.7 0.75 1,198,859 1.22 The Company also issued warrants to purchase an aggregate of 31,970 1.83
Liquidity	Liquidity The Company has incurred substantial net losses from operations since its inception, including net losses of $ 28,156 29,321 332,061 As of August 31, 2015, the Company had cash and cash equivalents of $ 8,095 The Company has incurred recurring losses and expects to incur additional losses related to the continued development of its business, including research and development, seed production and operations, and sales and marketing. There is no assurance that the Company will achieve profitable operations, or if achieved, can be sustained on a continued basis.
Restructuring	Restructuring On October 11, 2013, the Company commenced the implementation of a plan (Plan) intended to further align expenditures with the Company's near-term commercial opportunity in Brazil, shift Northern Hemisphere sorghum breeding activities from College Station, Texas to a more appropriate location, de-emphasize research and development for U.S. cellulosic feedstocks, reduce costs and conserve cash. The actions taken under the Plan, which included, among others, a workforce reduction that impacted 16 August 31, 2014 . During 2014, the Company incurred total charges of approximately $ 1,600 900 400 300 1,600 1,000 500 100 On June 19, 2015, the Company announced the continued realignment of its business to focus on food and forage opportunities and biotechnology traits for sugarcane and other crops. As part of the realignment, the Company undertook a restructuring of its Brazilian seed operations. The restructuring of the Company's Brazilian seed operations, includes, among other actions, a workforce reduction that initially impacted 14 2 600 100 500 $500 100 19 800 100 700 200 600
Basis of Presentation	Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with the accounting principles generally accepted in the United States of America (GAAP) and with the Rules and Regulations of the Securities and Exchange Commission. The consolidated financial statements include the accounts of the Company and its subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions. This affects the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant items subject to such estimates and assumptions include the valuation of assets held for sale, inventory, deferred tax assets, common stock, stock options, and liability classified warrants. Actual results could differ from those estimates.
Cash Equivalents	Cash Equivalents The Company considers all highly liquid investments, with an original maturity of three months or less when purchased, to be cash equivalents. Cash equivalents totaled $ 3,792 2,174
Marketable Securities	Marketable Securities Marketable securities are classified as available for sale and are recorded at fair value, with the unrealized gains and losses, if any, net of taxes, reported as a component of shareholders' equity until realized or until a determination is made that an other-than-temporary decline in market value has occurred. In determining whether an other-than-temporary impairment exists for debt securities, management considers: (1) the length of time and the extent to which the fair value has been less than cost, (2) the financial condition and near-term prospects of the issuer and (3) the intent and ability of the Company to retain its investment in the issuer for a period of time sufficient to allow for any anticipated recovery in fair value. Management has determined that there has been no other-than-temporary impairment of its marketable securities. The cost of marketable securities sold is based upon the specific identification method and any realized gains or losses on the sale of investments are reflected as a component of interest income or expense. There were no sales of marketable securities during the years ended August 31, 2015 and 2014. The Company classifies marketable securities as current or non-current based upon whether such assets are reasonably expected to be realized in cash or sold or consumed during the normal operating cycle of the business.
Financial Instruments	Financial Instruments The carrying value of financial instruments such as cash and cash equivalents, accounts receivables, accounts payable, and accrued expenses approximate their fair value due to the short-term nature of these instruments. At each period end, the fair value of the long-term debt approximated carrying value based on interest rates currently available to the Company.
Fair Value of Financial Instruments	Fair Value of Financial Instruments Assets and liabilities recorded at fair value in the consolidated financial statements are categorized based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels that are directly related to the amount of subjectivity associated with the inputs to the valuation of these assets or liabilities are as follows: • Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company can access at the measurement date. • Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. • Level 3 inputs are unobservable inputs for the asset or liability. The following tables present the Company's financial assets that were measured at fair value on a recurring basis as of August 31, 2015 and 2014 by level within the fair value hierarchy: August 31, 2015 Level 1 Level 2 Level 3 Total Financial Assets Money market funds $ 3,732 $ — $ — $ 3,732 Certificates of deposit — available for sale — 60 — 60 Total $ 3,732 $ 60 $ — $ 3,792 All of the money market funds and certificates of deposit are included in cash and cash equivalents on the consolidated balance sheets. August 31, 2014 Level 1 Level 2 Level 3 Total Financial Assets Money market funds $ 2,114 $ — $ — $ 2,114 Certificates of deposit — available for sale — 4,240 — 4,240 Commercial paper — available for sale — 5,249 — 5,249 Corporate bonds — available for sale — 15,150 — 15,150 Total $ 2,114 $ 24,639 $ — $ 26,753 All of the money market funds and $ 60
Financial Liabilities	Financial Liabilities Certain common stock warrants have been classified as liabilities due to some features which could enable the holder to receive cash. 1,631 The fair value of the common stock warrant liabilities at August 31, 2015 was estimated using the following weighted-average assumptions: Year Ended August 31, 2015 Expected term (in years) 4.91 5.49 Expected volatility 69.80 Risk free interest rate 1.54 Expected dividend yield 0
Accounts Receivable	Accounts Receivable Accounts receivable represents amounts owed to the Company from product sales and collaborative research and government grants. The Company had no amounts reserved for doubtful accounts at August 31, 2015 and 2014 as the Company expected full collection of the accounts receivable balances. Customers representing greater than 10% of accounts receivable were as follows (in percentages): As of Customers 2015 2014 Customer B 23.7 59.5 Customer E 18.9 25.9 Customer F 38.2 ** Customer G 16.1 ** ** No balance Customers representing greater than 10% of revenues were as follows (in percentages): Year Ended August 31, Customers 2015 2014 Customer A ** 17.5 Customer B 33.5 41.9 Customer E 12.2 16.5 Customer F 13.1 11.6 Customer I 11.9 ** ** No revenue
Inventories and Inventory Valuation	Inventories and Inventory Valuation At August 31, 2015, inventory was fully reserved. At August 31, 2014, seed inventory consisted of work-in-process and finished goods for costs related to the Company's sorghum seeds in Brazil. When inventory costs exceed expected market value due to obsolescence or lack of demand, inventory write-downs are recorded for the difference between the cost and the market value in the period based on the Company's evaluation of such inventory.
Property and Equipment	Property and Equipment Property and equipment is stated at cost. Depreciation is provided using the straight-line method over the shorter of the estimated useful lives or the remaining life of the lease. Depreciation periods for the Company's property and equipment are as follows: Automobiles and trucks 3 5 Office, laboratory, farm and warehouse equipment and furniture 3 5 Leasehold improvements 3 10 Buildings 14 39
Assets Held for Sale	Assets Held for Sale The Company reclassifies long-lived assets to Assets Held for Sale when all required criteria for such reclassification are met. The assets are recorded at the lower of the carrying value or fair value less costs to sell. Assets held for sale must meet the following conditions: (1) management, having authority to approve the action, commits to a plan to sell the asset, (2) the asset is available for immediate sale in its present condition, (3) an active program to locate a buyer and other actions required to complete the plan to sell the asset have been initiated, (4) the sale of the asset is probable, and transfer of the asset is expected to qualify for recognition as a completed sale, within one year, (5) the asset is being actively marketed for sale at a price that is reasonable in relation to its current fair value, and (6) actions required to complete the plan indicate that it is unlikely that significant changes to the plan will be made or that the plan will be withdrawn. In connection with an agreement the Company entered into on March 31, 2014 to sell its facility and certain equipment located in College Station, Texas, a determination was made that the assets met the criteria to be classified as held for sale and the fair value for the related assets was in excess of their carrying amount. Accordingly, the Company recorded a charge of $ 464 1,152 688 688 395 869 474 Fair value of the assets held for sale was determined using an appraisal for certain assets and resale information available for certain assets.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets Long-lived assets, such as property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. To the extent that an impairment indicator has occurred, recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset exceeds the fair value of the asset.
Stock-Based Compensation	Stock-Based Compensation The Company accounts for stock-based compensation arrangements with employees using a fair value method under ASC Topic 718, Compensation – Stock Compensation, The fair value method requires the Company to estimate the fair value of stock-based payment awards on the date of grant using an option pricing model. The Company uses an option pricing model to estimate the fair value of stock options granted that are expensed on a straight-line basis over the vesting period. The Company accounts for stock options issued to non-employees based on the estimated fair value of the awards using the option pricing model. The measurement of stock-based compensation to non-employees is subject to periodic adjustments as the underlying equity instruments vest, and the resulting change in value, if any, is recognized in the Company's consolidated statements of operations during the period the related services are rendered. The Company accounts for restricted stock awards based on the quoted market price of the Company's common stock on the date of grant that are expensed on a straight-line basis over the vesting period.
Revenue Recognition	Revenue Recognition Revenues are recognized when the following criteria are met: (1) persuasive evidence of an arrangement exists; (2) transfer of product or technology has been completed or services have been rendered; (3) the fee is fixed or determinable; and (4) collectability is reasonably assured. To date, the Company's primary source of revenues has been derived from collaborative research agreements and government grants and to a lesser extent, product sales. Product Sales Product sales are derived from seed and biomass sales, and trait fees. Product sales are recognized, net of discounts and allowances, once passage of title and risk of loss have occurred and contractually specified acceptance criteria have been met, provided all other revenue recognition criteria have also been met. Collaborative Research and Government Grants From time to time, the Company has entered into research and development collaboration agreements with third parties, including a large agriculture supplier, a consumer goods conglomerate and several biofuel producers. In addition, the Company has received grants from government agencies such as the Department of Energy (DOE) and the United States Department of Agriculture (USDA). The research and development collaboration agreements typically provide the Company with multiple revenue streams, which may include up-front, non-refundable fees for licensing certain of the Company's technologies, government grants and fees for research and development activities, and contingent milestone payments based upon achievement of contractual criteria. • Technology License Fees • Government Grants — The Company receives payments from government entities in the form of government grants. Government grants generally provide the Company with cost reimbursement for certain types of expenditures in return for research and development activities over a contractually defined period, as well an allocated portion of overhead expenses. Revenues from government grants are recognized in the period during which the related costs are incurred, provided substantially all the conditions under which the government grants were provided have been met and the Company has only perfunctory obligations outstanding. • Research and Development Fees • Milestone Fees The Company has earned research funding revenues from several agreements with the DOE, the USDA, USAID and several leading biofuel producers whereby the Company performed research activities and received revenues that partially reimbursed its expenses incurred. Under such grants and agreements, the Company retained a proprietary interest in the products and technology it developed. These expense reimbursements primarily consisted of direct expense sharing arrangements. The Company recorded revenue related to these grants and collaboration agreements of approximately $ 1,630 1,980
Software and Services	Software and Services During the years ended August 31, 2015 and 2014, the Company provided services related to software arrangements that involve (1) significant production, modification or customization and (2) post contract customer support (PCS). The customer has the option, annually, to extend the arrangement or elect to receive only maintenance. The Company does not have vendor specific objective evidence (VSOE) related to these components. In addition, there are substantive acceptance provisions related to the production, modification or customization. The company applies the completed contract method to the arrangement. However, only costs related to the production, modification or customization are deferred. Revenue is recognized upon acceptance of the production, modification or customization as that is later that the expiration of the annual PCS period. Revenue related to these arrangements was $ 656 278 The Company also had an arrangement that included a license, installation services and PCS. As the Company does not have VSOE for the elements, the Company has billings in excess of cash until PCS is the only undelivered element and will recognize revenue over the remaining PCS period. There was no revenue related to these arrangements during 2015 and 2014.
Billings in Excess of Costs	Billings in Excess of Costs
Research and Development	Research and Development Research and development expenses principally consist of personnel costs related to the Company's research and development staff as well as depreciation of research and development assets. Research and development expenses also include costs incurred for laboratory supplies, reimbursable costs associated with government grants and collaborative agreements, third-party contract payments, consultants, facility and related overhead costs.
Income Taxes	Income Taxes The Company accounts for income taxes in accordance with ASC 740, Income Taxes The Company accounts for unrecognized tax benefits also in accordance with ASC 740, Income Taxes August 31, 2015 and 2014, and did not recognize interest or penalties in the Statements of Operations during the years ended August 31, 2015 and 2014. The major jurisdictions in which the Company files income tax returns include the federal and state jurisdictions within the United States and Brazil, where it has a subsidiary. The tax years after 2009 remain open to examination by federal and state taxing jurisdictions and the tax years after 2011 remain open to examination by foreign jurisdictions. However, the Company has NOLs beginning in 1998 which would cause the statute of limitations to remain open for the year in which the NOL was incurred.
Foreign Currency Translation	Foreign Currency Translation The Brazilian real is the functional currency of the Company's subsidiary in Brazil and the Mexican Peso is the functional currency of the Company's subsidiary in Mexico. Accordingly, assets and liabilities of those operations are translated into United States dollars using the current exchange rate in effect at the balance sheet date and equity accounts are translated into United States dollars using historical rates. Revenues and expenses are translated at the weighted average rate of exchange during the reporting period. Gains and losses from foreign currency translation adjustments are represented as a component of accumulated other comprehensive loss.
Accumulated Other Comprehensive Loss	Accumulated Other Comprehensive Loss The Company's unrealized gains and losses on available-for-sale securities and foreign currency translation adjustments represents the components of comprehensive loss and have been disclosed in the consolidated statements of stockholders' equity. The following summarizes the changes in the balances of each component of accumulated comprehensive income (loss) during the years presented: Accumulated Foreign Unrealized Other Currency Gains (Losses) Comprehensive Translation on Securities Loss Balance at August 31, 2013 $ (684 ) $ (12 ) $ (696 ) Comprehensive gain 100 1 101 Balance at August 31, 2014 (584 ) (11 ) (595 ) Comprehensive gain 1,346 11 1,357 Balance at August 31, 2015 $ 762 $ - $ 762
Basic and Diluted Net Loss Per Share	Basic and Diluted Net Loss Per Share Basic net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding. Diluted net loss per common share is computed by dividing net loss available to common stockholders by the weighted average number of common shares and dilutive potential common share equivalents then outstanding, to the extent they are dilutive. Potential common shares consist of shares issuable upon the exercise of stock options and warrants (using the treasury stock method), and the weighted average conversion of the convertible preferred stock into shares of common stock (using the if-converted method). Dilutive net loss per share is the same as basic net loss per share for all periods presented because the effects of potentially dilutive items were anti-dilutive. The following potentially dilutive, common share equivalents were excluded from the calculation of diluted net loss per common share because their effect was anti-dilutive for each of the periods presented: Year Ended August 31, 2015 2014 Options to purchase common stock 409,763 396,504 Warrants to purchase common stock 2,775,083 320,255 Total 3,184,846 716,759
Segment and geographic information	Segment information Management has determined that it has one business activity and operates in one segment as it only reports financial information on an aggregate and consolidated basis to its Chief Executive Officer, who is the Company's chief operating decision maker.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In July 2013, the FASB issued ASU 2013-11, Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists. In May 2014, the Financial Accounting Standards Board issued the Accounting Standards Update (“ASU”) 2014-09 Revenue from Contracts with Customers (Topic 606) For a public entity, ASU 2014-09 is effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. Early application is not permitted. An entity must apply ASU 2014-09 using either the full retrospective approach, by restating all years presented, or the cumulative effect at the date of adoption approach. We are currently assessing the impact that these changes will have on our consolidated financial statements and therefore are unable to quantify such impact or determine the method of adoption. In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements - Going Concern Sub-topic 205-40. The new guidance addresses management's responsibility to evaluate whether there is substantial doubt about an entity's ability to continue as a going concern and to provide related footnote disclosures. This ASU is effective for interim and annual periods beginning on or after December 15, 2016, and early adoption is permitted. The Company does not expect the adoption of this guidance to have a material impact on its financial position or results of operations.

Summary of Significant Accoun21

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Aug. 31, 2015
Summary of Significant Accounting Policies [Abstract]
Schedule of Financial Assets Measured at Fair Value on Recurring Basis	August 31, 2015 Level 1 Level 2 Level 3 Total Financial Assets Money market funds $ 3,732 $ — $ — $ 3,732 Certificates of deposit — available for sale — 60 — 60 Total $ 3,732 $ 60 $ — $ 3,792 August 31, 2014 Level 1 Level 2 Level 3 Total Financial Assets Money market funds $ 2,114 $ — $ — $ 2,114 Certificates of deposit — available for sale — 4,240 — 4,240 Commercial paper — available for sale — 5,249 — 5,249 Corporate bonds — available for sale — 15,150 — 15,150 Total $ 2,114 $ 24,639 $ — $ 26,753
Schedule of weighted-average assumptions used in estimation of fair value of the common stock warrant liabilities	Year Ended August 31, 2015 Expected term (in years) 4.91 5.49 Expected volatility 69.80 Risk free interest rate 1.54 Expected dividend yield 0
Schedule of Customers Representing Greater than Ten Percent of Accounts Receivable	As of Customers 2015 2014 Customer B 23.7 59.5 Customer E 18.9 25.9 Customer F 38.2 ** Customer G 16.1 ** ** No balance
Schedule of Customers Representing Greater than Ten Percent of Revenue	Year Ended August 31, Customers 2015 2014 Customer A ** 17.5 Customer B 33.5 41.9 Customer E 12.2 16.5 Customer F 13.1 11.6 Customer I 11.9 ** ** No revenue
Schedule of Depreciation Period for Property and Equipment	Automobiles and trucks 3 5 Office, laboratory, farm and warehouse equipment and furniture 3 5 Leasehold improvements 3 10 Buildings 14 39
Schedule of Accumulated Other Comprehensive Income	Accumulated Foreign Unrealized Other Currency Gains (Losses) Comprehensive Translation on Securities Loss Balance at August 31, 2013 $ (684 ) $ (12 ) $ (696 ) Comprehensive gain 100 1 101 Balance at August 31, 2014 (584 ) (11 ) (595 ) Comprehensive gain 1,346 11 1,357 Balance at August 31, 2015 $ 762 $ - $ 762
Schedule of Potentially Dilutive, Common Share Equivalents Excluded from Calculation of Diluted Net Loss Per Common Share	Year Ended August 31, 2015 2014 Options to purchase common stock 409,763 396,504 Warrants to purchase common stock 2,775,083 320,255 Total 3,184,846 716,759

Marketable Securities (Tables)

Marketable Securities (Tables)	12 Months Ended
	Aug. 31, 2015
Marketable Securities [Abstract]
Schedule of Available for Sale Securities	August 31, 2014 Gross Gross Amortized Unrealized Unrealized Available for sale securities Cost Gain Loss Fair Value Certificates of Deposit $ 4,244 $ - $ (4 ) $ 4,240 Commercial Paper 5,249 - - 5,249 Corporate Bonds 15,157 - (7 ) 15,150 Total $ 24,650 $ - $ (11 ) $ 24,639

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Aug. 31, 2015
Inventories [Abstract]
Schedule of Inventories	August 31, 2014 Work in process $ 20 Seed inventory 64 Total inventories $ 84

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Aug. 31, 2015
Property and Equipment [Abstract]
Summary of Property and Equipment	As of August 31, 2015 2014 Land $ 43 $ 43 Automobiles and trucks 44 1,113 Buildings 1,215 1,215 Office, laboratory, farm and warehouse equipment and furniture 10,863 12,718 Leasehold improvements 5,659 5,659 17,824 20,748 Less accumulated depreciation and amortization (16,566 ) (17,752 ) Property and equipment, net $ 1,258 $ 2,996

Accounts Payable and Accrued 25

Accounts Payable and Accrued Expenses (Tables)	12 Months Ended
	Aug. 31, 2015
Accounts Payable and Accrued Expenses [Abstract]
Schedule of Accounts Payable and Accrued Expenses	As of August 31, 2015 2014 Accounts payable $ 2,000 $ 1,406 Accrued payroll and related expenses 1,581 2,303 Research and development contracts 283 123 Taxes 395 - Other 143 446 $ 4,402 $ 4,278

Long-Term Debt (Tables)

Long-Term Debt (Tables)	12 Months Ended
	Aug. 31, 2015
Long-Term Debt [Abstract]
Summary of Long-Term Debt	As of August 31, 2014 Capital Leases $ 88 Less current portion (70 ) $ 18

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	12 Months Ended
	Aug. 31, 2015
Stock-Based Compensation [Abstract]
Schedule of Fair Value of Employee Stock Options Estimated Using Weighted Average Assumptions	Year ended August 31, 2015 2014 Expected term (in years) 5.50-6.08 5.50-6.08 Expected volatility 79 -83 % 83 -87 % Risk free interest rate 1.66 -2.06 % 1.62 -2.04 % Expected dividend yield 0 % 0 %
Summary of Stock-Based Compensation Costs Included in Operating Expenses and Total Intrinsic Value of Options Exercised	Year ended August 31, 2015 2014 Stock-based compensation costs for employee stock options $ 2,270 $ 3,074 Fair value changes of collaboration warrants (5 ) (6 ) Total stock-based compensation costs included in operating expenses $ 2,265 $ 3,068
Summary of Stock Option Transactions under Option Plans	Weighted Average Shares Exercise Price Options outstanding at August 31, 2013 348,830 $ 59.92 Options granted 98,004 10.16 Options forfeited (50,330 ) 67.60 Options outstanding at August 31, 2014 396,504 46.62 Options granted 41,738 3.75 Options forfeited (28,479 ) 23.41 Options outstanding at August 31, 2015 409,763 $ 43.87
Summary of Information about Stock Options Outstanding and Exercisable	Weighted- Weighted- Remaining Average Number Remaining Average Range of Number Contractual Exercise Vested and Contractual Exercise Exercise Price Outstanding Life Price Exercisable Life Price $ 1.96 5.06 36,004 9.52 $ 4.00 187 8.76 $ 5.06 $ 7.26 15.60 137,803 5.26 $ 12.24 134,754 5.19 $ 12.30 $ 26.24 32.40 56,831 3.50 $ 29.53 50,326 2.95 $ 29.83 $ 45.68 61.60 103,286 3.67 $ 54.93 102,719 3.65 $ 54.91 $ 96.80 137.28 75,839 6.26 $ 113.77 58,178 6.24 $ 114.68 409,763 346,164
Summary of Restricted Stock Transactions under Option Plans	Weighted Average Grant Date Shares Fair Value Restricted stock outstanding and unvested at August 31, 2013 36,311 $ 44.40 Restricted stock granted 41,032 $ 10.48 Restricted stock vested (32,877 ) $ 16.96 Restricted stock forfeited (6,648 ) $ 38.00 Restricted stock outstanding and unvested at August 31, 2014 37,818 $ 32.58 Restricted stock granted 9,125 $ 4.20 Restricted stock vested (8,690 ) $ 36.63 Restricted stock forfeited (1,011 ) $ 12.77 Restricted stock outstanding and unvested at August 31, 2015 37,242 $ 25.17

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Aug. 31, 2015
Income Taxes [Abstract]
Schedule of Income Tax Expense Attributable to Income (Loss) before Income Taxes	Current Deferred Total Year ended August 31, 2015 U.S. federal $ — $ — $ — State and local 1 — 1 $ 1 $ — $ 1 Current Deferred Total Year ended August 31, 2014 U.S. federal $ — $ — $ — State and local 1 — 1 $ 1 $ — $ 1
Schedule of Income Tax Expense Differs from Amount Computed by Applying Federal Income Tax Rate	Year Ended Year Ended August 31, August 31, 2015 2014 Computed “expected” tax expense $ (9,584 ) $ (9,969 ) Increase (reduction) in income taxes resulting from: Stock-based compensation 625 774 State and local income taxes, net of federal income tax benefit 1 1 Foreign rate differential — — Warrants modification and changes in fair value — — Other 21 12 Change in valuation allowance 8,937 9,183 Income tax expense $ 1 $ 1
Summary of Tax Effects of Temporary Differences that Give Rise to Significant Portions of Deferred Tax Assets and Liabilities	August 31, August 31, 2015 2014 Deferred tax assets: Accrued liabilities $ 240 $ 279 Other assets 157 169 Inventory capitalization 266 446 Deferred revenue 348 139 Total current deferred tax assets 1,011 1,031 Noncurrent assets: Depreciation 1,834 2,310 Inventory reserves 2,973 2,689 Deferred rent 22 29 Other assets 1,013 859 Net operating loss carryforward 112,373 101,485 Federal and state tax credit carryforward 8,919 8,919 Total noncurrent deferred tax assets 127,133 116,291 Total deferred tax assets 128,145 117,323 Less valuation allowance (128,145 ) (117,323 ) Net deferred tax assets $ — $ —

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Aug. 31, 2015
Commitments and Contingencies [Abstract]
Schedule of Future Minimum Payments under Noncancelable Operating Leases	Operating leases 2016 $ 621 2017 606 2018 618 2019 631 2020 51 Total minimum lease payments $ 2,527

Research Collaboration Agreem30

Research Collaboration Agreements (Tables)	12 Months Ended
	Aug. 31, 2015
Research Collaboration Agreements [Abstract]
Schedule of Future Minimum Payments under Company's Research Collaboration	2016 $ 602 2017 50 $ 652

Summary of Significant Accoun31

Summary of Significant Accounting Policies (Narrative) (Details) $ / shares in Units, $ in Thousands	Aug. 26, 2015USD ($)$ / sharesshares	Aug. 19, 2015USD ($)positions	Jul. 30, 2015USD ($)$ / sharesshares	Jun. 19, 2015USD ($)positions	Apr. 08, 2015	Jun. 02, 2014USD ($)	Mar. 10, 2014USD ($)$ / sharesshares	Mar. 31, 2014USD ($)	Aug. 31, 2015USD ($)	Aug. 31, 2014USD ($)positions	Aug. 31, 2013USD ($)
Accounting Policies [Line Items]
Reverse stock split ratio					0.125
Shares issued at public offering, shares | shares	1,598,478		1,200,000				23,000,000
Underwriters exercise of public offering over-allotment, shares | shares							3,000,000
IPO price, per share | $ / shares	$ 0.01		$ 0.01
Shares issued at public offering, price per share | $ / shares	$ 1.22		$ 1.296				$ 1
Proceeds from public offering	$ 1,700		$ 1,000				$ 20,800		$ 2,794	$ 20,751
Number of share of common stock to be issued upon exercise of each warrant | shares	0.75		1
Exercise price of warrant | $ / shares	$ 1.22		$ 1.62
Warrant issued to purchase stock | shares	1,198,859
Net loss									(28,156)	(29,321)
Accumulated deficit									(332,061)	$ (303,905)
Workforce reduction, number of positions impacted | positions										16
Workforce reduction, one-time severance expense										$ 900
Workforce reduction, total charges incurred										1,600
Workforce reduction, continuation of salary and benefits										400
Workforce reduction, other costs										300
Cash and cash equivalents									8,095	3,423	$ 8,881
Cash equivalents									3,792	2,174
Fair value of common stock warrant liabilities									1,631
Other expenses				$ 395				$ 464
Carrying amount of assets held for sale				869				1,152
Assets held for sale, net				474				$ 688
Proceeds from sale of facility and equipment						$ 688			60	810
Revenue from software and services									656	278,000
Workforce reduction [Member]
Accounting Policies [Line Items]
Estimated total charges to be incurred				600
Severance costs		$ 100		$ 100
Cash payments related to restructuring									500
Expected cash payments related to restructuring									100
Workforce reduction [Member] | Brazil [Member]
Accounting Policies [Line Items]
Number of workforce | positions		19		14
Estimated total charges to be incurred		$ 800
Workforce reduction [Member] | U.S [Member]
Accounting Policies [Line Items]
Number of workforce | positions				2
One-time severance cost [Member]
Accounting Policies [Line Items]
Severance costs		$ 700		$ 500
Cash payments related to restructuring									200
Expected cash payments related to restructuring									600
Placement agent [Member]
Accounting Policies [Line Items]
Exercise price of warrant | $ / shares	$ 1.83		$ 1.944
Warrant issued to purchase stock | shares	31,970		24,000
Several Agreements [Member]
Accounting Policies [Line Items]
Collaborative research and government grants									$ 1,630	1,980
Research and Development Expense [Member]
Accounting Policies [Line Items]
Workforce reduction, total charges incurred										1,000
Cost of Sales [Member]
Accounting Policies [Line Items]
Workforce reduction, total charges incurred										500
General and Administrative Expense [Member]
Accounting Policies [Line Items]
Workforce reduction, total charges incurred										$ 100
Ceres Sementes do Brasil Ltda [Member]
Accounting Policies [Line Items]
Percentage of ownership									99.90%
CS Semillas de Mexico, S.de L. de C.V. [Member]
Accounting Policies [Line Items]
Percentage of ownership									99.90%

Summary of Significant Accoun32

Summary of Significant Accounting Policies (Schedule of Financial Assets Measured at Fair Value on Recurring Basis) (Details) - USD ($) $ in Thousands	Aug. 31, 2015	Aug. 31, 2014
Financial Instruments Measured At Fair Value On Recurring Basis [Line Items]
Available for sale		$ 24,639
Cash and cash equivalents [Member]
Financial Instruments Measured At Fair Value On Recurring Basis [Line Items]
Certificates of deposit		60
Fair Value, Measurements, Recurring [Member]
Financial Instruments Measured At Fair Value On Recurring Basis [Line Items]
Total	$ 3,792	26,753
Fair Value, Measurements, Recurring [Member] | Money market funds [Member]
Financial Instruments Measured At Fair Value On Recurring Basis [Line Items]
Money market funds	3,732	2,114
Fair Value, Measurements, Recurring [Member] | Certificates of Deposit [Member]
Financial Instruments Measured At Fair Value On Recurring Basis [Line Items]
Available for sale	60	4,240
Fair Value, Measurements, Recurring [Member] | Commercial Paper [Member]
Financial Instruments Measured At Fair Value On Recurring Basis [Line Items]
Available for sale		5,249
Fair Value, Measurements, Recurring [Member] | Corporate bonds [Member]
Financial Instruments Measured At Fair Value On Recurring Basis [Line Items]
Available for sale		15,150
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Financial Instruments Measured At Fair Value On Recurring Basis [Line Items]
Total	3,732	2,114
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Money market funds [Member]
Financial Instruments Measured At Fair Value On Recurring Basis [Line Items]
Money market funds	$ 3,732	$ 2,114
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Certificates of Deposit [Member]
Financial Instruments Measured At Fair Value On Recurring Basis [Line Items]
Available for sale
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Commercial Paper [Member]
Financial Instruments Measured At Fair Value On Recurring Basis [Line Items]
Available for sale
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Corporate bonds [Member]
Financial Instruments Measured At Fair Value On Recurring Basis [Line Items]
Available for sale
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Financial Instruments Measured At Fair Value On Recurring Basis [Line Items]
Total	$ 60	$ 24,639
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Money market funds [Member]
Financial Instruments Measured At Fair Value On Recurring Basis [Line Items]
Money market funds
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Certificates of Deposit [Member]
Financial Instruments Measured At Fair Value On Recurring Basis [Line Items]
Available for sale	$ 60	$ 4,240
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Commercial Paper [Member]
Financial Instruments Measured At Fair Value On Recurring Basis [Line Items]
Available for sale		5,249
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Corporate bonds [Member]
Financial Instruments Measured At Fair Value On Recurring Basis [Line Items]
Available for sale		$ 15,150
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Financial Instruments Measured At Fair Value On Recurring Basis [Line Items]
Total
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Money market funds [Member]
Financial Instruments Measured At Fair Value On Recurring Basis [Line Items]
Money market funds
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Certificates of Deposit [Member]
Financial Instruments Measured At Fair Value On Recurring Basis [Line Items]
Available for sale
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Commercial Paper [Member]
Financial Instruments Measured At Fair Value On Recurring Basis [Line Items]
Available for sale
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Corporate bonds [Member]
Financial Instruments Measured At Fair Value On Recurring Basis [Line Items]
Available for sale

Summary of Significant Accoun33

Summary of Significant Accounting Policies (Schedule of Weighted-Average Assumptions Used in Estimation of Fair Value of Common Stock Warrant Liabilities ) (Details) - Common stock warrant [Member]	12 Months Ended
	Aug. 31, 2015
Weighted-average assumptions used in estimation of fair value of the common stock warrant liabilities [Line Items]
Expected volatility	69.80%
Risk free interest rate	1.54%
Expected dividend yield	0.00%
Minimum [Member]
Weighted-average assumptions used in estimation of fair value of the common stock warrant liabilities [Line Items]
Expected term	4 years 10 months 28 days
Maximum [Member]
Weighted-average assumptions used in estimation of fair value of the common stock warrant liabilities [Line Items]
Expected term	5 years 5 months 26 days

Summary of Significant Accoun34

Summary of Significant Accounting Policies (Schedule of Customers Representing Greater than Ten Percent of Accounts Receivable) (Details) - Accounts receivables [Member]	12 Months Ended
	Aug. 31, 2015	Aug. 31, 2014
Customer B [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Concentration risk, percentage	23.70%	59.50%
Customer E [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Concentration risk, percentage	18.90%	25.90%
Customer F [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Concentration risk, percentage	38.20%		[1]
Customer G [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Concentration risk, percentage	16.10%		[1]
[1]	No balance

Summary of Significant Accoun35

Summary of Significant Accounting Policies (Schedule of Customers Representing Greater than Ten Percent of Revenues) (Details) - Revenues [Member]	12 Months Ended
	Aug. 31, 2015		Aug. 31, 2014
Customer A [Member]
Revenue, Major Customer [Line Items]
Concentration risk, percentage		[1]	17.50%
Customer B [Member]
Revenue, Major Customer [Line Items]
Concentration risk, percentage	33.50%		41.90%
Customer E [Member]
Revenue, Major Customer [Line Items]
Concentration risk, percentage	12.20%		16.50%
Customer F [Member]
Revenue, Major Customer [Line Items]
Concentration risk, percentage	13.10%		11.60%
Customer I [Member]
Revenue, Major Customer [Line Items]
Concentration risk, percentage	11.90%			[1]
[1]	No revenue

Summary of Significant Accoun36

Summary of Significant Accounting Policies (Schedule of Depreciation Periods for Property and Equipment) (Details)	12 Months Ended
	Aug. 31, 2015
Automobiles and Trucks [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment useful life	3 years
Automobiles and Trucks [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment useful life	5 years
Office, Laboratory, Farm and Warehouse Equipment and Furniture [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment useful life	3 years
Office, Laboratory, Farm and Warehouse Equipment and Furniture [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment useful life	5 years
Leasehold Improvements [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment useful life	3 years
Leasehold Improvements [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment useful life	10 years
Buildings [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment useful life	14 years
Buildings [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment useful life	39 years

Summary of Significant Accoun37

Summary of Significant Accounting Policies (Summary of Accumulated Other Comprehensive Income) (Details) - USD ($) $ in Thousands	12 Months Ended
	Aug. 31, 2015	Aug. 31, 2014
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	$ (595)	$ (696)
Comprehensive gain	1,357	101
Balance	762	(595)
Foreign Currency Translation [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	(584)	(684)
Comprehensive gain	1,346	100
Balance	762	(584)
Unrealized Gains (Losses) on Securities [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	(11)	(12)
Comprehensive gain	$ 11	1
Balance		$ (11)

Summary of Significant Accoun38

Summary of Significant Accounting Policies (Schedule of Potentially Dilutive, Common Share Equivalents Excluded from Calculation of Diluted Net Loss Per Common Share) (Details) - shares	12 Months Ended
	Aug. 31, 2015	Aug. 31, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities excluded from computation of earnings per share	3,184,846	716,759
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities excluded from computation of earnings per share	409,763	396,504
Common Stock Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities excluded from computation of earnings per share	2,775,083	320,255

Marketable Securities (Schedule

Marketable Securities (Schedule of Available for Sale Securities) (Details) $ in Thousands	Aug. 31, 2014USD ($)
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	$ 24,650
Gross Unrealized Gain
Gross Unrealized Loss	$ (11)
Fair Value	24,639
Cash and cash equivalents [Member]
Schedule of Available-for-sale Securities [Line Items]
Certificates of deposit	60
Commercial paper	1,199
Certificates of Deposit [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	$ 4,244
Gross Unrealized Gain
Gross Unrealized Loss	$ (4)
Fair Value	4,240
Commercial Paper [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	$ 5,249
Gross Unrealized Gain
Gross Unrealized Loss
Fair Value	$ 5,249
Corporate Bonds [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	$ 15,157
Gross Unrealized Gain
Gross Unrealized Loss	$ (7)
Fair Value	$ 15,150

Inventories (Details)

Inventories (Details) - USD ($) $ in Thousands	Aug. 31, 2015	Aug. 31, 2014
Inventories [Abstract]
Work in process		$ 20
Seed inventory		64
Total inventories		$ 84

Property and Equipment (Details

Property and Equipment (Details) - USD ($) $ in Thousands	Aug. 31, 2015	Aug. 31, 2014
Property, Plant and Equipment [Line Items]
Property plant and equipment gross	$ 17,824	$ 20,748
Less accumulated depreciation and amortization	(16,566)	(17,752)
Property and equipment, net	1,258	2,996
Land [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment gross	43	43
Automobiles and Trucks [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment gross	44	1,113
Buildings [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment gross	1,215	1,215
Office, Laboratory, Farm and Warehouse Equipment and Furniture [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment gross	10,863	12,718
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment gross	$ 5,659	$ 5,659

Accounts Payable and Accrued 42

Accounts Payable and Accrued Expenses (Details) - USD ($) $ in Thousands	Aug. 31, 2015	Aug. 31, 2014
Accounts Payable and Accrued Expenses [Abstract]
Accounts payable	$ 2,000	$ 1,406
Accrued payroll and related expenses	1,581	2,303
Research and development contracts	283	$ 123
Taxes	395
Other	143	$ 446
Accounts payable and accrued expenses	$ 4,402	$ 4,278

Long-Term Debt (Summary of Long

Long-Term Debt (Summary of Long-Term Debt) (Details) - USD ($) $ in Thousands	Aug. 31, 2015	Aug. 31, 2014	Aug. 31, 2013
Debt Disclosure [Line Items]
Long-term Debt		$ 88	$ 236
Less current portion		(70)
Long-term debt, net of current portion		18
Capital Leases [Member]
Debt Disclosure [Line Items]
Long-term Debt		$ 88

Stock-Based Compensation (Narra

Stock-Based Compensation (Narrative) (Details) - USD ($)	12 Months Ended
	Aug. 31, 2015	Aug. 31, 2014	Aug. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation, shares reserved for issuance	844,374
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized stock compensation expense		$ 91,000
Unrecognized stock-based compensation expense, weighted average period of recognition		1 year 25 days
Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average grant date fair value of options	$ 3.04	$ 7.28
Unrecognized stock compensation expense	$ 1,159,000	$ 2,993,000
Unrecognized stock-based compensation expense, weighted average period of recognition		1 year 5 months 16 days
Ceres, Inc. 2011 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation, option term	10 years
Share-based compensation, increase in shares reserved for issuance			187,500,000
Share-based compensation, shares available for future grant	135,456
Common stock granted during period		2,288
Weighted average grant date fair value of common stock		$ 7.28
Stock grant expense		$ 16,700
Weighted Average [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average grant date fair value of common stock	$ 3.76	$ 10.24
Minimum [Member] | Ceres, Inc. 2011 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation, vesting period	4 years
Maximum [Member] | Ceres, Inc. 2011 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation, vesting period	5 years

Stock-Based Compensation (Fair

Stock-Based Compensation (Fair Value of Employee Stock Options Estimated Using Weighted Average Assumptions) (Details) - Employee Stock Options [Member]	12 Months Ended
	Aug. 31, 2015	Aug. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (in years)	3 years 22 days
Expected volatility, minimum	79.00%	83.00%
Expected volatility, maximum	83.00%	87.00%
Risk free interest rate, minimum	1.66%	1.62%
Risk free interest rate, maximum	2.06%	2.04%
Expected dividend yield	0.00%	0.00%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (in years)	5 years 6 months	5 years 6 months
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (in years)	6 years 29 days	6 years 29 days

Stock-Based Compensation (Stock

Stock-Based Compensation (Stock-Based Compensation Costs Included in Operating Expenses and Total Intrinsic Value of Options Exercised) (Details) - USD ($) $ in Thousands	12 Months Ended
	Aug. 31, 2015	Aug. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation costs	$ 2,265	$ 3,068
Employee Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation costs	2,270	3,074
Collaboration warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation costs	$ (5)	$ (6)

Stock-Based Compensation (Summa

Stock-Based Compensation (Summary of Stock Option Transactions under Option Plans) (Details) - Stock Options [Member] - $ / shares	12 Months Ended
	Aug. 31, 2015	Aug. 31, 2014
Shares
Options outstanding	396,504	348,830
Options granted	41,738	98,004
Options forfeited	(28,479)	(50,330)
Options outstanding	409,763	396,504
Weighted Average Exercise Price
Options outstanding	$ 46.62	$ 59.92
Options granted	3.75	10.16
Options forfeited	23.41	67.60
Options outstanding	$ 43.87	$ 46.62

Stock-Based Compensation (Sum48

Stock-Based Compensation (Summary of Information about Stock Options Outstanding and Exercisable) (Details) - Stock Options [Member]	12 Months Ended
	Aug. 31, 2015$ / sharesshares
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number Outstanding | shares	409,763
Number Vested and Exercisable | shares	346,164
Exercise Price 1 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number Outstanding | shares	36,004
Remaining Contractual Life	9 years 6 months 7 days
Weighted-Average Exercise Price	$ 4
Number Vested and Exercisable | shares	187
Remaining Contractual Life	8 years 9 months 4 days
Weighted-Average Exercise Price	$ 5.06
Exercise Price 1 [Member] | Minimum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Price	1.96
Exercise Price 1 [Member] | Maximum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Price	$ 5.06
Exercise Price 2 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number Outstanding | shares	137,803
Remaining Contractual Life	5 years 3 months 4 days
Weighted-Average Exercise Price	$ 12.24
Number Vested and Exercisable | shares	134,754
Remaining Contractual Life	5 years 2 months 8 days
Weighted-Average Exercise Price	$ 12.30
Exercise Price 2 [Member] | Minimum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Price	7.26
Exercise Price 2 [Member] | Maximum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Price	$ 15.60
Exercise Price 3 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number Outstanding | shares	56,831
Remaining Contractual Life	3 years 6 months
Weighted-Average Exercise Price	$ 29.53
Number Vested and Exercisable | shares	50,326
Remaining Contractual Life	2 years 11 months 12 days
Weighted-Average Exercise Price	$ 29.83
Exercise Price 3 [Member] | Minimum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Price	26.24
Exercise Price 3 [Member] | Maximum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Price	$ 32.40
Exercise Price 4 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number Outstanding | shares	103,286
Remaining Contractual Life	3 years 8 months 1 day
Weighted-Average Exercise Price	$ 54.93
Number Vested and Exercisable | shares	102,719
Remaining Contractual Life	3 years 7 months 24 days
Weighted-Average Exercise Price	$ 54.91
Exercise Price 4 [Member] | Minimum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Price	45.68
Exercise Price 4 [Member] | Maximum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Price	$ 61.60
Exercise Price 5 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number Outstanding | shares	75,839
Remaining Contractual Life	6 years 3 months 4 days
Weighted-Average Exercise Price	$ 113.77
Number Vested and Exercisable | shares	58,178
Remaining Contractual Life	6 years 2 months 26 days
Weighted-Average Exercise Price	$ 114.68
Exercise Price 5 [Member] | Minimum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Price	96.80
Exercise Price 5 [Member] | Maximum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Price	$ 137.28

Stock-Based Compensation (Sum49

Stock-Based Compensation (Summary of Restricted Stock Transactions under Option Plans) (Details) - Restricted Stock [Member] - $ / shares	12 Months Ended
	Aug. 31, 2015	Aug. 31, 2014
Shares
Restricted stock outstanding and unvested	37,818	36,311
Restricted stock granted	9,125	41,032
Restricted stock vested	(8,690)	(32,877)
Restricted stock forfeited	(1,011)	(6,648)
Restricted stock outstanding and unvested	37,242	37,818
Weighted Average Exercise Price
Restricted stock outstanding and unvested	$ 32.58	$ 44.40
Restricted stock granted	4.20	10.48
Restricted stock vested	36.63	16.96
Restricted stock forfeited	12.77	38
Restricted stock outstanding and unvested	$ 25.17	$ 32.58

Stockholders' Equity (Details)

Stockholders' Equity (Details) - USD ($)	Aug. 26, 2015	Jul. 30, 2015	Mar. 10, 2014	Aug. 31, 2015	Dec. 31, 2011	Jun. 30, 2011	Aug. 31, 2007	May. 31, 2006	Aug. 31, 2015	Aug. 31, 2014	Mar. 07, 2014
Stockholders Equity Note Disclosure [Line Items]
IPO price, per share	$ 0.01	$ 0.01
Common Stock, shares authorized				240,000,000					240,000,000	240,000,000	490,000,000
Preferred stock, shares authorized											10,000,000
Warrant issued to purchase stock	1,198,859
Exercise price of warrants issued	$ 1.22	$ 1.62
Change in value of warrants recognized as research and development expense									$ 9,684,000	$ 14,156,000
Warrants issued exercisable price	0.75	1
Noble Agreement Warrants [Member]
Stockholders Equity Note Disclosure [Line Items]
Warrant issued to purchase stock								16,667
Exercise price of warrants issued								$ 240
Warrant issued, number of shares vesting in equal installments						4,167		4,167
Warrant issued, earliest exercisable period								2 years
Change in value of warrants recognized as research and development expense									$ 624,400
Warrant issued, vested				16,667					16,667
Warrant issued, expiration date						May 18, 2017
Noble Agreement Warrants [Member] | Period 1 [Member]
Stockholders Equity Note Disclosure [Line Items]
Class of warrant or right number of shares vesting in equal installments, date								May 19, 2009
Noble Agreement Warrants [Member] | Period 2 [Member]
Stockholders Equity Note Disclosure [Line Items]
Class of warrant or right number of shares vesting in equal installments, date						May 19, 2015		May 19, 2011
Noble Agreement Warrants [Member] | Period 3 [Member]
Stockholders Equity Note Disclosure [Line Items]
Class of warrant or right number of shares vesting in equal installments, date								May 19, 2013
Noble Agreement Warrants [Member] | Period 4 [Member]
Stockholders Equity Note Disclosure [Line Items]
Class of warrant or right number of shares vesting in equal installments, date								May 19, 2015
Texas A and M University System Agreement Warrants [Member] | Sponsored Research and Intellectual Property Rights Agreement [Member]
Stockholders Equity Note Disclosure [Line Items]
Warrant issued to purchase stock							8,333
Exercise price of warrants issued							$ 240
Estimated fair value of warrants				$ 0					$ 0
Estimated fair value of warrants, risk free rate									0.74%
Estimated fair value of warrants, volatility rate									72.10%
Estimated fair value of warrants, expected term									1 year 11 months 26 days
Estimated fair value of warrants, dividend yield rate									0.00%
Change in value of warrants recognized as research and development expense									$ 0
Warrant issued, expiration date							Aug. 28, 2017
Texas A and M University System Agreement Warrants [Member] | Ip Rights Agreement [Member]
Stockholders Equity Note Disclosure [Line Items]
Warrant issued to purchase stock					8,333
Exercise price of warrants issued					$ 114.40
Estimated fair value of warrants				3,800					$ 3,800
Estimated fair value of warrants, risk free rate									2.21%
Estimated fair value of warrants, volatility rate									88.90%
Estimated fair value of warrants, expected term									11 years 7 months 6 days
Estimated fair value of warrants, dividend yield rate									0.00%
Change in value of warrants recognized as research and development expense									$ 1,800
Warrant issued, expiration date					Sep. 24, 2026
2014 Public Offering Warrants [Member]
Stockholders Equity Note Disclosure [Line Items]
Warrant issued to purchase stock			60,000
Exercise price of warrants issued			$ 12
Estimated fair value of warrants			$ 305,000
Estimated fair value of warrants, risk free rate			1.64%
Estimated fair value of warrants, volatility rate			84.20%
Estimated fair value of warrants, expected term			5 years
Estimated fair value of warrants, dividend yield rate			0.00%
Warrant issued, date from which warrants are exercisable			Mar. 4, 2015
Warrant issued, expiration date			Mar. 4, 2019
July 2015 Public Offering Warrants [Member]
Stockholders Equity Note Disclosure [Line Items]
Warrant issued to purchase stock		1,200,000
Exercise price of warrants issued		$ 1.62
Estimated fair value of warrants		$ 760,000		$ 755,600					755,600
Estimated fair value of warrants, risk free rate		1.62%		1.54%
Estimated fair value of warrants, volatility rate		69.50%		69.80%
Estimated fair value of warrants, expected term		5 years 6 months		5 years 4 months 28 days
Estimated fair value of warrants, dividend yield rate		0.00%		0.00%
July 2015 Placement Agent Warrants [Member]
Stockholders Equity Note Disclosure [Line Items]
Warrant issued to purchase stock		24,000
Exercise price of warrants issued		$ 1.944
Estimated fair value of warrants		$ 13,300		$ 13,200					13,200
Estimated fair value of warrants, risk free rate		1.62%		1.62%
Estimated fair value of warrants, volatility rate		69.50%		69.80%
Estimated fair value of warrants, expected term		5 years		4 years 10 months 24 days
Estimated fair value of warrants, dividend yield rate		0.00%		0.00%
August 2015 Public Offering Warrants [Member]
Stockholders Equity Note Disclosure [Line Items]
Warrant issued to purchase stock	1,198,859
Exercise price of warrants issued	$ 1.22
Estimated fair value of warrants	$ 863,500			$ 844.2					844.2
Estimated fair value of warrants, risk free rate	1.49%			1.54%
Estimated fair value of warrants, volatility rate	69.80%			69.80%
Estimated fair value of warrants, expected term	5 years 6 months			5 years 6 months
Estimated fair value of warrants, dividend yield rate	0.00%			0.00%
Warrants issued exercisable price	0.75
August 2015 Placement Agent Warrants [Member]
Stockholders Equity Note Disclosure [Line Items]
Warrant issued to purchase stock	31,970
Exercise price of warrants issued	$ 1.83
Estimated fair value of warrants	$ 18,700			$ 18,300					$ 18,300
Estimated fair value of warrants, risk free rate	1.49%			1.54%
Estimated fair value of warrants, volatility rate	69.80%			69.80%
Estimated fair value of warrants, expected term	5 years			5 years
Estimated fair value of warrants, dividend yield rate	0.00%			0.00%

Income Taxes (Income Tax Expens

Income Taxes (Income Tax Expense Attributable to Income (Loss) before Income Taxes) (Details) - USD ($) $ in Thousands	12 Months Ended
	Aug. 31, 2015	Aug. 31, 2014
Current Income Tax Expense Benefit
U.S. federal
State and local	$ 1	$ 1
Current Income Tax Expense	$ 1	$ 1
Deferred Income Tax Expense
U.S. federal
State and local
Deferred Income Tax Expense
Income Tax Expense Benefit
U.S. federal
State and local	$ 1	$ 1
Income tax expense	$ 1	$ 1

Income Taxes (Narrative) (Detai

Income Taxes (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Aug. 31, 2015	Aug. 31, 2014
Income Taxes [Line Items]
Federal income tax rate	34.00%
Excess tax benefits associated with the exercise of non-qualified stock options, restricted stock grants, and disqualifying dispositions of incentive stock option stock	$ 911	$ 957
Valuation allowance	128,145	$ 117,323
Internal Revenue Service (IRS) [Member]
Income Taxes [Line Items]
Net operating loss carryforwards	273,908
Internal Revenue Service (IRS) [Member] | Research Tax Credit Carryforward [Member]
Income Taxes [Line Items]
Tax credit carryforwards	$ 8,907
Tax credit carryforwards, expiration date	2,029
Internal Revenue Service (IRS) [Member] | Minimum [Member]
Income Taxes [Line Items]
Net operating loss carryforwards expiration date	2,018
Internal Revenue Service (IRS) [Member] | Maximum [Member]
Income Taxes [Line Items]
Net operating loss carryforwards expiration date	2,035
State and Local Jurisdiction [Member]
Income Taxes [Line Items]
Net operating loss carryforwards	$ 196,789
State and Local Jurisdiction [Member] | Alternative Minimum Tax [Member]
Income Taxes [Line Items]
Tax credit carryforwards	$ 17
State and Local Jurisdiction [Member] | Minimum [Member]
Income Taxes [Line Items]
Net operating loss carryforwards expiration date	2,015
State and Local Jurisdiction [Member] | Maximum [Member]
Income Taxes [Line Items]
Net operating loss carryforwards expiration date	2,035
Foreign Tax Authority [Member]
Income Taxes [Line Items]
Net operating loss carryforwards	$ 25,833

Income Taxes (Income Tax Expe53

Income Taxes (Income Tax Expense Differs from Amount Computed by Applying Federal Income Tax Rate) (Details) - USD ($) $ in Thousands	12 Months Ended
	Aug. 31, 2015	Aug. 31, 2014
Income Taxes [Abstract]
Computed "expected" tax expense	$ (9,584)	$ (9,969)
Stock-based compensation	625	774
State and local income taxes, net of federal income tax benefit	$ 1	$ 1
Foreign rate differential
Warrants modification and changes in fair value
Other	$ 21	$ 12
Change in valuation allowance	8,937	9,183
Income tax expense	$ 1	$ 1

Income Taxes (Summary of Tax Ef

Income Taxes (Summary of Tax Effects of Temporary Differences that Give Rise to Significant Portions of Deferred Tax Assets and Liabilities) (Details) - USD ($) $ in Thousands	Aug. 31, 2015	Aug. 31, 2014
Deferred tax assets:
Accrued liabilities	$ 240	$ 279
Other assets	157	169
Inventory capitalization	266	446
Deferred revenue	348	139
Total current deferred tax assets	1,011	1,031
Noncurrent assets:
Depreciation	1,834	2,310
Inventory reserves	2,973	2,689
Deferred rent	22	29
Other assets	1,013	859
Net operating loss carryforward	112,373	101,485
Federal and state tax credit carryforward	8,919	8,919
Total noncurrent deferred tax assets	127,133	116,291
Total deferred tax assets	128,145	117,323
Less valuation allowance	$ (128,145)	$ (117,323)
Net deferred tax assets

401(k) Benefit Plan (Details)

401(k) Benefit Plan (Details) - USD ($) $ in Thousands	12 Months Ended
	Aug. 31, 2015	Aug. 31, 2014
401(k) Benefit Plan [Abstract]
Benefit plan, maximum percentage of employee contribution	60.00%
Benefit plan, percentage of employer matching contribution	50.00%
Benefit plan, maximum percentage the employer may contribute	4.00%
Benefit plan, percentage of employer matching contribution immediately vesting percentage	25.00%
Benefit plan, percentage of employer matching contribution annual vesting percentage	25.00%
Benefit plan, employer matching contribution vesting period		3 years
Benefit plan, recorded expense	$ 132	$ 207

Commitments and Contingencies56

Commitments and Contingencies (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Aug. 31, 2015	Aug. 31, 2014
Commitments and Contingencies [Abstract]
Operating lease expiration period	2,020
Reimbursement for leasehold improvement	$ 270
Rental expense	$ 457	$ 440

Commitments and Contingencies57

Commitments and Contingencies (Summary of Future Minimum Payments under Noncancelable Operating Leases) (Details) $ in Thousands	Aug. 31, 2015USD ($)
Operating leases
2,016	$ 621
2,017	606
2,018	618
2,019	631
2,020	51
Total minimum lease payments	$ 2,527

Research Collaboration Agreem58

Research Collaboration Agreements (Narrative) (Details) - USD ($)	1 Months Ended
	Sep. 24, 2011	Aug. 31, 2007	May. 31, 2006	Aug. 26, 2015	Jul. 30, 2015	Dec. 31, 2011
Collaboration Agreements [Line Items]
Warrant issued to purchase stock				1,198,859
Exercise price of warrants issued				$ 1.22	$ 1.62
Noble Agreement Warrants [Member]
Collaboration Agreements [Line Items]
Warrant issued to purchase stock			16,667
Exercise price of warrants issued			$ 240
Noble Research Program Agreement [Member]
Collaboration Agreements [Line Items]
Funding of research expenses			$ 3,800,000
Collaboration agreement date			Jul. 31, 2012
Noble Research Program Agreement [Member] | Collaboration Agreement July Thirty One Twenty Thirteen [Member]
Collaboration Agreements [Line Items]
Funding of research expenses			$ 82,700
Collaboration agreement date			Jul. 31, 2013
Noble Research Program Agreement [Member] | Collaboration Agreement July Thirty One Twenty Fourteen [Member]
Collaboration Agreements [Line Items]
Funding of research expenses			$ 85,300
Collaboration agreement date			Jul. 31, 2014
Sponsored Research and Intellectual Property Rights Agreement [Member]
Collaboration Agreements [Line Items]
Funding of research expenses		$ 5,100,000
Agreement expiry date	Sep. 23, 2026
Sponsored Research and Intellectual Property Rights Agreement [Member] | Texas A and M University System Agreement Warrants [Member]
Collaboration Agreements [Line Items]
Warrant issued to purchase stock		8,333
Exercise price of warrants issued		$ 240
Ip Rights Agreement [Member]
Collaboration Agreements [Line Items]
Agreement expiry date	Sep. 23, 2026
Ip Rights Agreement [Member] | Texas A and M University System Agreement Warrants [Member]
Collaboration Agreements [Line Items]
Warrant issued to purchase stock						8,333
Exercise price of warrants issued						$ 114.40

Research Collaboration Agreem59

Research Collaboration Agreements (Summary of Future Minimum Payments under Company's Research Collaboration) (Details) - Research Collaboration Agreements [Member] $ in Thousands	Aug. 31, 2015USD ($)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
2,016	$ 602
2,017	50
Contractual Obligation, Total	$ 652